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Abstract
Background: Vertebroplasty is a promising but as yet unproven treatment for painful
osteoporotic vertebral fractures. It involves radiographic-guided injection of various types of bone
cement directly into the vertebral fracture site. Uncontrolled studies and two controlled quasi-
experimental before-after studies comparing volunteers who were offered treatment to those who
refused it, have suggested an early benefit including rapid pain relief and improved function.
Conversely, several uncontrolled studies and one of the controlled before-after studies have also
suggested that vertebroplasty may increase the risk of subsequent vertebral fractures, particularly
in vertebrae adjacent to treated levels or if cement leakage into the adjacent disc has occurred. As
yet, there are no completed randomised controlled trials of vertebroplasty for osteoporotic
vertebral fractures. The aims of this participant and outcome assessor-blinded randomised
placebo-controlled trial are to i) determine the short-term efficacy and safety (3 months) of
vertebroplasty for alleviating pain and improving function for painful osteoporotic vertebral
fractures; and ii) determine its medium to longer-term efficacy and safety, particularly the risk of
further fracture over 2 years.
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BMC Musculoskeletal Disorders 2008, 9:156 http://www.biomedcentral.com/1471-2474/9/156Design: A double-blind randomised controlled trial of 200 participants with one or two recent
painful osteoporotic vertebral fractures. Participants will be stratified by duration of symptoms (<
and ≥ 6 weeks), gender and treating radiologist and randomly allocated to either the treatment or
placebo. Outcomes will be assessed at baseline, 1 week, 1, 3, 6, 12 and 24 months. Outcome
measures include overall, night and rest pain on 10 cm visual analogue scales, quality of life
measured by the Assessment of Quality of Life, Osteoporosis Quality of Life and EQ-5D
questionnaires; participant perceived recovery on a 7-point ordinal scale ranging from 'a great deal
worse' to 'a great deal better'; disability measured by the Roland-Morris Disability Questionnaire;
timed 'Up and Go' test; and adverse effects. The presence of new fractures will be assessed by
radiographs of the thoracic and lumbar spine performed at 12 and 24 months.
Discussion: The results of this trial will be of major international importance and findings will be
immediately translatable into clinical practice.
Trial registration: Australian Clinical Trial Register # [ACTRN012605000079640]
Background
Vertebral fractures are the most common form of oste-
oporotic fracture and yet are often an under-recognised
cause of morbidity and perhaps mortality in our commu-
nity [1,2]. Apart from analgesia, bed rest and physical
therapy, all of which may be of value, there are no effec-
tive interventions. While calcitonin has been demon-
strated to have an analgesic effecin two placebo-
controlled studies [3,4], it is not registered for use for this
purpose in Australia. Interventions that effectively man-
age the pain, shorten the recovery time and eliminate the
need for extended nursing and rehabilitation care would
be of great value to both reduce the personal burden
borne by those affected, and reduce the high management
costs.
Vertebroplasty is a promising but as yet unproven new
treatment for painful osteoporotic vertebral fractures [5].
It was first developed in France in the late 1980s to treat
spinal hemangiomas and subsequently osteolytic metas-
tases and myeloma [6]. It involves percutaneous injection
of poly-methyl methacrylate (PMMA) or a like material,
opacified with barium sulfate into the involved vertebral
body under fluoroscopic and/or CT guidance. Injection of
2–4 millilitres of cement (combined with a radio-opaque
substance such as barium) via a transpedicular approach
is usually performed under local anaesthesia combined
with neurolept analgesia and may be done as an outpa-
tient procedure or in a short hospital stay. The mechanism
of pain relief with vertebroplasty is not known. Theories
include thermal or chemical local effects on nerve end-
ings, and a mechanical effect of stabilization of an unsta-
ble (ie. moveable) fracture [7]. The semisolid mixture of
PMMA has been shown to restore strength and stiffness of
vertebral bodies in post-mortem studies [7].
Since 1994, there have been numerous published case
reports and case series ranging from 1 to 260 patients,
treated for painful osteoporotic spinal fractures [8-16]. In
these retrospective and uncontrolled prospective reports,
vertebroplasty has been associated with an often immedi-
ate, dramatic and sustained improvement in pain and
increased mobility in most patients. However uncon-
trolled studies tend to overestimate treatment benefit for
a variety of reasons [17]. They fail to take into account the
natural history of the condition which is to improve over
time; they make no allowance for the statistical artefact of
'regression to the mean'; and do not adjust for the placebo
response which is likely to be accentuated with an inva-
sive procedure [18].
Two recent quasi-experimental controlled before-after
studies that compared volunteers who were offered treat-
ment to those who refused it, have also suggested an early
benefit of vertebroplasty in terms of rapid pain relief and
improved function [19,20]. However, these study designs
are vulnerable to substantial bias. Volunteers may have a
better outcome than those who decline to receive a new
therapy as a function of self-selection. In one study, those
who agreed were more disabled at baseline and so had
greater potential to improve [20]; while participants in the
other study were treated early in the course of the condi-
tion and most were treated as inpatients, so the results
may not pertain to patients who have had pain for longer
than a few weeks [19].
In general, the risk of subsequent vertebral fracture once a
vertebral fracture has occurred is very high – for example,
the risk within a year of a single vertebral fracture has been
estimated to be ~20% in those with untreated osteoporo-
sis and ~10% in those treated with bisphosphonates [21].
Several recent uncontrolled studies have suggested an
increased incidence of subsequent vertebral fractures with
vertebroplasty, particularly in vertebrae adjacent to
treated levels or if cement leakage into the adjacent disc
has occurred [22,23], while two controlled before-afterPage 2 of 9
(page number not for citation purposes)
BMC Musculoskeletal Disorders 2008, 9:156 http://www.biomedcentral.com/1471-2474/9/156studies have yielded conflicting results [19,20]. A possible
increased risk of fracture in adjacent vertebrae may be due
to an alteration in the distribution of biomechanical load-
ing [24] and/or negative effects on bone remodelling
(local acceleration of bone resorption) as a result of the
treatment itself or a cytokine-mediated foreign-body reac-
tion at the cement-bone interface [25]. Treated vertebrae
have been found to be stronger and stiffer after vertebro-
plasty compared to osteoporotic bone [26,27].
Vertebroplasty may be of immense value but its potential
benefits need to be weighed up with its potential risks. It
is essential to quantify any increased risk of further verte-
bral fractures following vertebroplasty compared with
conservative care and to determine whether there are any
strategies that can minimise the risk. This study will deter-
mine the efficacy and safety of vertebroplasty for acute
painful osteoporotic vertebral fracture compared with pla-
cebo in a randomised participant-blinded and outcome
assessor-blinded trial. It will quantify the risk of develop-
ing new vertebral fractures in the first and second year fol-
lowing vertebroplasty in comparison to conservative care.
Aims
The aims of this randomised placebo-controlled trial are
to:
i) determine the short-term efficacy and safety (3 months)
of vertebroplasty for alleviating pain and improving func-
tion for painful osteoporotic vertebral fractures; and
ii) determine its medium to longer-term efficacy and
safety, particularly the excess risk of further fracture over 2
years.
Methods
Trial design
This is a participant and outcome assessor-blinded multi-
centre randomised placebo-controlled trial with 2-year
follow-up (Figure 1).
Ethics
Ethics approval has been received from the Human
Research Ethics Committees of Monash University,
Cabrini Health, Melbourne Health, Western Health,
Southern Health, Northern Health, and the Alfred Hospi-
tal, all in Melbourne, Australia.
Participants
Participants will be recruited from general practitioners,
specialists who manage acute osteoporotic vertebral frac-
tures and hospital inpatient and emergency departments.
To increase awareness of the trial, we will advertise in local
media, include regular updates in relevant medical organ-
isation newsletters, and send regular newsletters to our
referral base.
All potential participants will be screened to determine
eligibility according to the following inclusion and exclu-
sion criteria. Participants will have back pain of no more
than 12 months duration. Osteoporotic spinal fractures
will be confirmed by thoracic and lumbar spine radio-
graph and, if not already obtained, all participants (unless
contraindicated) will have an MRI examination of the
thoracic and lumbar spine to determine the position,
extent, age and stability of the vertebral fracture and to
ensure no exclusion criteria exist. Only participants with
one or two recent vertebral fractures, defined as vertebral
collapse and oedema or fracture line within the vertebral
body, will be included. When an MRI is unable to be per-
formed, a CT scan, to determine the position and extent of
the vertebral fracture/s, and bone scan, to determine the
presence of increased uptake in a distribution compatible
with recent vertebral fracture will be required.
Exclusion criteria will be: the presence of more than two
recent spinal fractures; presence of malignant disease in
the spine; neurological complications; osteoporotic verte-
bral collapse of > 90%; fracture through or destruction of
posterior wall; retropulsed bony fragment or bony frag-
ments impinging on the spinal cord; discitis; osteomyeli-
tis; uncontrolled sepsis; non-correctable coagulation
disorder; medical conditions that make the patient ineli-
gible for emergency decompressive surgery should it be
necessary to treat a procedure complication (e.g. severe
heart and/or lung disease, renal failure); current malig-
nancy; dementia; previous vertebroplasty; inability to give
informed consent; an/or likelihood of non-compliance
with follow up.
Randomisation
Participants who fulfil inclusion criteria and consent to
take part in the trial will be randomised in permuted
blocks of 4 and 6, stratified by treating radiologist, gender
and duration of symptoms (< 6 weeks versus = 6 weeks),
to receive either the active or placebo regimen according
to a computer-generated table of random numbers cre-
ated by the study biostatistician. To ensure treatment allo-
cation concealment, just prior to the procedure the
treating radiologist contacts a central receptionist who
provides the appropriate opaque sealed envelope contain-
ing the treatment allocation of the participant according
to their identification number. Only the telephone recep-
tionist has access to the allocation schedule and she has
no other role in the trial.
Interventions
All procedures will be standardised across sites. Patients
will be positioned prone on the angiographic table andPage 3 of 9
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Diagram of Recruitment and Participation ProcessFigure 1
Diagram of Recruitment and Participation Process.
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BMC Musculoskeletal Disorders 2008, 9:156 http://www.biomedcentral.com/1471-2474/9/156preliminary screening will be performed to identify the
fracture level. A 25G intravenous cannula will be inserted
into the dorsum of the hand or forearm and neurolept
sedation/analgesia of midazolam and fentanyl (doses
appropriate for weight and height) will be given as
required during the procedure by the radiologist perform-
ing the procedure. A cardiac monitor clip will be placed
on the other hand. For all patients, the skin will be pre-
pared with an iodine-based solution and a drape will be
placed over the body. All procedures will be standardised
with care taken to preserve blinding in the event that
patients do not have total amnesia. Throughout the pro-
cedure, blood pressure, heart rate, oxygen saturation and
neurological status will be monitored. Procedures will be
performed in hospitals with neurosurgical or orthopaedic
surgical support in case of unforeseen complications and
patients will be monitored for 4 hours following the pro-
cedure in the Day Procedure Ward prior to being dis-
charged. Analgesia as required will be given following the
procedure.
Percutaneous Vertebroplasty
The left pedicle of the fracture site will be identified with
a metallic marker and a 25G needle will be used to infil-
trate the skin overlying the pedicle. A longer 23G needle
will be used to infiltrate the periosteum of the posterior
lamina. A scalpel will be used to make a small incision in
the skin. A 13G needle (Cook, USA) with a bevelled edge
will be placed posterolateral relative to the eye of the pedi-
cle. Gentle tapping using a hammer will be performed to
guide the needle through the pedicle down into the ante-
rior two thirds of the fractured vertebral body. Bi-plane
imaging if available will guide needle placement, alterna-
tively the image intensifier screen will be rotated from the
A-P to the transverse planes and back again to monitor the
progress of the needle as it passes through the bone. Both
A-P and lateral images will be recorded with the needle in
the correct position. Intravertebral contrast injection
venography will be optional. Some operators find the
localisation of veins to be useful. Ten ml dilute contrast
will be injected through connecting tubing into the needle
to assess filling of epidural veins with digital subtraction
radiography if venography is used.
At the nursing trolley, the pre-packaged PMMA with
radio-opacifier will be mixed to an appropriate consist-
ency. This will be poured into a 20 ml syringe from which
several 1 ml syringes will be filled. The stylet will be
removed from the 13G needle transfixed within the verte-
bral body and approximately 3–4 millilitres PMMA will
slowly be injected into the vertebral body rotating the nee-
dle in order to direct the passage of bone cement to the
affected area. The working time for the injection is approx-
imately 2 minutes. Having confirmed satisfactory infiltra-
tion of the vertebral body with bone cement in both A-P
and lateral planes (with the image intensifier), the needle
will be slowly removed by rotation. A unilateral approach
will be used unless there is inadequate instillation of
cement, in which case a bipedicular approach will be
used. Extreme care will be taken to ensure that no leakage
of cement occurs either into a vein or outside the bone.
The injection will be stopped when significant resistance
is met, or when the cement reaches the posterior quarter
of the vertebral body or when there is escape into extraos-
seous structures or veins. All patients in the active group
will receive 1 gram cephalothin IV as prophylaxis against
infection.
Placebo treatment
Many patients who undergo vertebroplasty recall the tap-
ping sensation against the vertebra. For this reason, sub-
jects assigned to placebo will undergo the same
procedures to insertion of the 13G needle to rest on the
lamina. At that point, the central sharp stylet will be
removed and replaced by a blunt ended stylet. To simulate
vertebroplasty, gentle tapping with a hammer will be per-
formed sufficient to generate enough noise and vibration
to be heard and felt by the patient. The blunt ended stylet
will be less likely to penetrate the bone during tapping
with a hammer. At regular intervals the image intensifier
will be rotated into the lateral planes and then back to the
AP plane. At the nursing trolley, some PMMA will be
reconstituted with barium and saline such that the smell
permeates throughout the room. Several 1 ml syringes
will be filled as for the active group and injection will be
simulated.
All participants receive usual care according to the discre-
tion of their treating doctor. Analgesia use is unrestricted
and its use will be recorded at baseline and follow up. All
treating physicians receive an information sheet about the
trial as well as a copy of the most up-to-date guidelines for
management of osteoporosis. Management of osteoporo-
sis is at the discretion of the participants' treating physi-
cians.
Outcome Assessment
The same blinded assessor will assess all participants at
baseline. Baseline data will include gender, date of birth,
height, weight, risk factors for osteoporosis including use
of certain medications such as corticosteroids and anti-
convulsants, smoking and alcohol use, medications for
osteoporosis, usual level of exercise, fracture history, cur-
rent therapy for vertebral fracture. If not already available,
plain films of the thoracic and lumbosacral spine will be
obtained. If not performed within the previous year, bone
mineral density measurement will also be performed.
All participants will be evaluated after the procedure at 1
week, 1, 3, 6, 12 and 24 months using mailed question-Page 5 of 9
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ise response rates.
The following outcomes will be assessed at each time
point:
Overall pain, pain at rest, and pain in bed at night (over
the last week) will be measured on a 0–10 numerical scale
comprising a vertical line labelled "no pain" at the bottom
(0) and "maximal imaginable pain" at the top (10) [28].
A range of standardised, self-report quality of life meas-
ures will be used:
The Assessment of Quality of Life (AQoL) is a health-
related quality of life instrument comprising 15 items in 5
dimensions (Illness, Independent Living, Social Relation-
ships, Physical Senses, and Psychological Well-being)
[29,30]. It is well validated, responds to rapid changes in
health status and is sensitive to changes in the frail elderly
[29]. The AQoL incorporates utility weights that have
been derived from an Australian population sample using
time-trade off (TTO). The range of scores is between 0.00
(death) and 1.00 (perfect health), with higher scores rep-
resenting better health-related quality of life. The utility
score can be used in cost-utility analyses and calculation
of Quality-Adjusted Life Years.
The quality of life questionnaire of the European Founda-
tion for Osteoporosis (QUALEFFO) is an osteoporosis-
specific measure comprising 41 items organised in five
domains (Pain, Physical Function, Social Function, Gen-
eral Health Perception and Mental Function) [31]. Each
domain score and QUALEFFO total scores are expressed
on a 100-point scale, with lower scores corresponding to
better health-related quality of life. It has demonstrated
reliability between patients with and without vertebral
fracture and QUALEFFO scores have been shown to
increase progressively with increasing numbers of verte-
bral fractures [32].
The EQ-5D is a standard general quality of life instrument,
measuring five domains (Mobility, Self Care, Usual Activ-
ities, Pain/Discomfort and Anxiety/Depression), with
three levels in each, ranging in severity from no problem,
some problem to extreme problem [33]. Respondents are
then classified into one of 243 (35) health states, with the
best imaginable health state representing someone who
reports the highest level of functioning in each domain.
This instrument has been used in studies of patients with
and without vertebral fractures [34,35].
The Roland Morris Disability questionnaire measures
physical disability due to low back pain [36] but has also
been shown to be an effective tool in evaluating vertebro-
plasty outcomes [37]. The original questionnaire con-
sisted of 24 questions and was derived from the Sickness
Impact Profile (SIP), with qualification 'because of my
back pain' added to each question [36]. We will use a
modified version comprising 28 items, modified to
reduce the redundancy of some of the questions and to
add items that better reflect changes in the patient [37].
Items are scored from 0 (no disability) to 28 (maximum
disability). An additional question regarding the use of
wheelchairs has been added and is scaled from 1 (no dis-
ability) to 4 (maximum disability).
Participants' perceived recovery with respect to pain,
fatigue and overall health will be measured on 7-point
ordinal scales ranging from 'a great deal worse' to 'a great
deal better' at all follow up time points. It will be used to
classify participants with a successful outcome, defined as
'moderately better' or ''a great deal better' across each indi-
cator.
At baseline, 12 and 24 months, all participants will be
assessed by the same blinded assessor who will administer
the timed 'Up and Go' test [38]. This measures the time it
takes a person to rise from a standard arm chair, walk to a
line on the floor 3 metres away, turn around, return to the
chair and sit down again. It is a widely used functional
measure in older people and has good reliability and
validity.
To determine the incidence of new vertebral fractures radi-
ologically, all participants will undergo plain film exami-
nation of the thoracic and lumbosacral spine at 12 and 24
months. Regular serial follow-up films are recommended
standard care following vertebroplasty to evaluate the
treated vertebrae and to look for fractures in untreated ver-
tebrae [25]. Two independent blinded radiologists will
read the radiographs using the well-validated and reliable
Genant semi quantitative method for identifying and
gauging the severity of the fracture [39]. A new vertebral
fracture will be defined as an increase in deformity grade
(equivalent to a decrease of >15% in any vertebral height)
from the baseline radiograph to the end of the study; or a
new fracture in an existing prevalent fracture if there is
progression to a higher grade of deformity (equivalent to
a further vertebral height reduction of >15%) [39].
Success of blinding will be assessed at the end of the study
by asking participants to indicate their treatment group.
Five response options will range from 'I am definitely in
placebo group', through to 'I am definitely in the vertebro-
plasty group', with 'don't know' as the central option.
Sample size
The primary outcome will be overall pain at 3 months.
Very large effects (e.g. >7 on a 10 point scale) have beenPage 6 of 9
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patients. People who undergo conventional treatment
will also tend to have some improvement as some acute
symptoms subside. To detect a large (i.e. at least a 2.5
unit) advantage of vertebroplasty over placebo in pain
score (SD = 3.0, α = 0.05, β = 0.80, 2-tailed t-test) we
would require only 24 participants per group. At 12 and
24 months we expect smaller differences to exist between
the groups due to the natural course of the disease (i.e.
improvements in the placebo group and likely adjustment
to the illness) and possibly a greater frequency of vertebral
fracture in the vertebroplasty group. Using the same
assumptions as above but considering a 15% advantage in
the vertebroplasty group (mean vertebroplasty improve-
ment = 4.0 units, mean placebo improvement = 2.5 units)
we would require 64 people in each group.
The most relevant adverse event from vertebroplasty may
be further vertebral fractures. A reasonable estimate for
the one year incidence of new fractures in women with at
least one fracture and not on preventive treatment is
about 20% based on new vertebral fractures observed in
the first year for the placebo arm of four risedronate clin-
ical trials [21]. Many participants in our trial are likely to
be on treatment for osteoporosis, which may theoretically
reduce the risk of further vertebral fracture by 50% to
around 10% [21,40,41]. In the two controlled before-after
studies there was between a zero and 3 fold increase in the
1 year new fracture risk [42,20]. The risk of fracture in the
second year is unknown but likely to be less than in the
first year. With 82 people in each group we will have 80%
power to detect a 3-fold excess in fractures in the vertebro-
plasty group (alpha = 0.05, 2-tailed Log rank test). While
this study is not specifically designed to assess small group
differences related to infrequent events, if medium to
large excesses in adverse events are present, the study is
adequately powered.
Health-related Quality of Life (AQoL utility score) is an
important global secondary outcome at 2 years. This is a
complex mix of benefits such as vertebral-specific reduc-
tion in pain and decreased distress, but may also involve
adverse events such as vertebral re-fracture or hip fracture.
The AQoL is an ideal generic instrument to capture broad
health-related changes – incorporating a mix of health
declines and improvements. With a sample size of 82,
there will be 80% power to detect a 0.13 change in Health
-related Quality of Life (utility). For example, the
improvement in the placebo group may be 0.10 units
compared with 0.23 in the vertebroplasty group (sd = 0.3,
α = 0.05, 2-tailed t-test). Compared with the disease-spe-
cific outcomes noted above, this magnitude of change can
be regarded as relatively small but clinically relevant [43];
hence the study is powered to detect even modest overall
benefits of vertebroplasty. To allow for attrition, we will
increase the sample by 20% to 100 patients per group.
Planned statistical analysis
Treatment groups will be examined for comparability at
baseline with respect to demographic and prognostic fac-
tors. An intention-to-treat analysis will be performed
using efficacy measures. Simple changes from baseline
will be assessed at each time point using t-tests or corre-
sponding nonparametric tests. Analysis of covariance will
be applied to assess differences in the 3-month endpoints
between groups after adjusting for baseline outcome val-
ues and other characteristics imbalanced at baseline if
required. Standard regression assumptions will be
assessed using diagnostic plots. Repeated measures analy-
sis using linear mixed models will include the 1-week, 1,
3, 6, 12 and 24-month outcomes and will assess con-
stancy of the vertebroplasty effect over time.
Time frame
The study will be conducted over a 6-year period.
Discussion and conclusion
Painful vertebral fractures complicating osteoporosis are a
substantial and growing public health problem leading to
severe morbidity and an increased burden on the health
care system. Interventions that effectively manage the
pain, shorten the recovery time, and eliminate the need
for extended nursing and rehabilitation care are lacking.
Such treatments would not only reduce the personal bur-
den borne by those people affected, they would also
reduce the high management costs. Vertebroplasty is a
promising intervention that has only been evaluated in
uncontrolled trials and controlled before-after studies, but
its effects have not yet been formally evaluated in rand-
omized controlled trials.
The outcome of our proposed research will be to establish
whether vertebroplasty is efficacious and safe compared to
placebo for painful osteoporotic vertebral fractures. The
findings of this research will be of major international
importance and will be immediately translatable into
clinical practice irrespective of the results. If our results are
positive, we will have scientific evidence to support the
currently uncorroborated endorsement of this interven-
tion. If, on the other hand, our results indicate that its effi-
cacy is no greater than placebo (and it may do more
harm), then this will also significantly impact upon cur-
rent practices.
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